MITF in melanoma: Mechanisms behind its expression and activity

Cellular and Molecular Life Sciences

Volumn 72, Issue 7, 2015, Pages 1249-1260

  Hartman, Mariusz L ^a   Czyz, Malgorzata ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

BRAF^{V600E< sup>; Gene regulation; Melanoma cancer plasticity; MicroRNA; MITF; Oncogene; Transcription factor}

Indexed keywords

BRG1 PROTEIN; BRM PROTEIN; CIGLITAZONE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FISETIN; HISTONE DEACETYLASE INHIBITOR; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MICRORNA 182; MITOGEN ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR GLI2; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR SOX10;

ALTERNATIVE RNA SPLICING; CANCER RESISTANCE; GENE AMPLIFICATION; GENE MUTATION; GENE STRUCTURE; HUMAN; MELANOMA; MELANOMA CELL; METASTATIC MELANOMA; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR GENE; OVERALL SURVIVAL; PROTEIN PHOSPHORYLATION; REVIEW; SUMOYLATION; TRANSCRIPTION REGULATION; TUMOR REGRESSION; BIOLOGICAL MODEL; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PATHOLOGY; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; MODELS, GENETIC; PROTEIN BIOSYNTHESIS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR MICROENVIRONMENT;

EID: 84929365675     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-014-1791-0     Document Type: Review

References (138)

1. Park HY, Kosmadaki M, Yaar M, Gilchrest BA (2009) Cellular mechanisms regulating human melanogenesis. Cell Mol Life Sci 66(9):1493-1506. doi: 10.1007/s00018-009-8703-8
2. Sommer L (2011) Generation of melanocytes from neural crest cells. Pigment Cell Melanoma Res 24(3):411-421. doi: 10.1111/j.1755-148X.2011.00834.x
3. Haq R, Fisher DE (2011) Biology and clinical relevance of the microphthalmia family of transcription factors in human cancer. J Clin Oncol 29(25):3474-3482. doi: 10.1200/JCO.2010.32.6223
4. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436(7047):117-122
5. Kumar SM, Dai J, Li S, Yang R, Yu H, Nathanson KL, Liu S, Zhou H, Guo J, Xu X (2013) Human skin neural crest progenitor cells are susceptible to BRAF(V600E)-induced transformation. Oncogene 33(7):832-841. doi: 10.1038/onc.2012.642
6. Regad T (2013) Molecular and cellular pathogenesis of melanoma initiation and progression. Cell Mol Life Sci 70(21):4055-4065. doi: 10.1007/s00018-013-1324-2
7. Pinner S, Jordan P, Sharrock K, Bazley L, Collinson L, Marais R, Bonvin E, Goding C, Sahai E (2009) Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. Cancer Res 69(20):7696-7977. doi: 10.1158/0008-5472.CAN-09-0781
8. Thurber AE, Douglas G, Sturm EC, Zabierowski SE, Smit DJ, Ramakrishnan SN, Hacker E, Leonard JH, Herlyn M, Sturm RA (2011) Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway. Oncogene 30(27):3036-3048. doi: 10.1038/onc.2011.33
9. Bell RE, Khaled M, Netanely D, Schubert S, Golan T, Buxbaum A, Janas MM, Postolsky B, Goldberg MS, Shamir R, Levy C (2014) Transcription factor/microRNA axis blocks melanoma invasion program by miR-211 targeting NUAK1. J Invest Dermatol 134(2):441-451. doi: 10.1038/jid.2013.340
10. Cheli Y, Giuliano S, Fenouille N, Allegra M, Hofman V, Hofman P, Bahadoran P, Lacour JP, Tartare-Deckert S, Bertolotto C, Ballotti R (2012) Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells. Oncogene 31(19):2461-2470. doi: 10.1038/onc.2011.425
11. Hoek KS, Schlegel NC, Eichhoff OM, Widmer DS, Praetorius C, Einarsson SO, Valgeirsdottir S, Bergsdteinsdottir K, Schepsky A, Dummer R, Steingrimsson E (2008) Novel MITF targets identified using a two-step DNA microarray strategy. Pigment Cell Melanoma Res 21(6):665-676. doi: 10.1111/j.1755-148X.2008.00505.x
12. Giuliano S, Cheli Y, Ohanna M, Bonet C, Beuret L, Bille K, Loubat A, Hofman V, Hofman P, Ponzio G, Bahadoran P, Ballotti R, Bertolotto C (2010) Microphthalmia-associated transcription factor controls the DNA damage response and a lineage-specific senescence program in melanomas. Cancer Res 70(9):3813-3822. doi: 10.1158/0008-5472.CAN-09-2913
13. Widmer DS, Cheng PF, Eichhoff OM, Belloni BC, Zipser MC, Schlegel NC, Javelaud D, Mauviel A, Dummer R, Hoek KS (2012) Systematic classification of melanoma cells by phenotype-specific gene expression mapping. Pigment Cell Melanoma Res 25(3):343-353. doi: 10.1111/j.1755-148X.2012.00986
14. Yajima I, Kumasaka MY, Thang ND, Goto Y, Takeda K, Iida M, Ohgami N, Tamura H, Yamanoshita O, Kawamoto Y, Furukawa K, Kato M (2011) Molecular network associated with MITF in skin melanoma development and progression. J Skin Cancer 2011:730170. doi: 10.1155/2011/730170
15. Hsiao JJ, Fisher DE (2014) The roles of microphthalmia-associated transcription factor and pigmentation in melanoma. Arch Biochem Biophys S0003-9861(14):00270-00277. doi: 10.1016/j.abb.2014.07.019
16. Hartman ML, Czyz M (2014) Pro-survival role of MITF in melanoma. J Invest Dermatol. doi: 10.1038/jid.2014.319
17. Hartman ML, Czyz M (2013) Anti-apoptotic proteins on guard of melanoma cell survival. Cancer Lett 331(1):24-34. doi: 10.1016/j.canlet.2013.01.010
18. Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, Frederick DT, Hurley AD, Nellore A, Kung AL, Wargo JA, Song JS, Fisher DE, Arany Z, Widlund HR (2013) Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell 23(3):1-14. doi: 10.1016/j.ccr.2013.02.003
19. Martina JA, Diab HI, Li H, Puertollano R (2014) Novel roles for the MiTF/TFE family of transcription factors in organelle biogenesis, nutrient sensing, and energy homeostasis. Cell Mol Life Sci 71(13):2483-2497. doi: 10.1007/s00018-014-1565-8
20. Eichhoff OM, Weeraratna A, Zipser MC, Denat L, Widmer DS, Xu M, Kriegl L, Kirchner T, Larue L, Dummer R, Hoek KS (2011) Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching. Pigment Cell Melanoma Res 24(4):631-642. doi: 10.1111/j.1755-148X.2011.00871.x
21. Eccles MR, He S, Ahn A, Slobbe LJ, Jeffs AR, Yoon HS, Baguley BC (2013) MITF and PAX3 play distinct roles in melanoma cell migration; outline of a "genetic switch" theory involving MITF and PAX3 in proliferative and invasive phenotypes of melanoma. Front Oncol 3:229. doi: 10.3389/fonc.2013.00229
22. Goding CR (2011) A picture of Mitf in melanoma immortality. Oncogene 30(20):2304-2306. doi: 10.1038/onc.2010.641
23. Bell RE, Levy C (2011) The three m's: melanoma, microphthalmia-associated transcription factor and microRNA. Pigment Cell Melanoma Res 24(6):1088-1106. doi: 10.1111/j.1755-148X.2011.00931.x
24. Carreira S, Goodall J, Denat L, Rodriguez M, Nuciforo P, Hoek KS, Testori A, Larue L, Goding CR (2006) Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev 20(24):3426-3439
25. Cheli Y, Giuliano S, Botton T, Rocchi S, Hofman V, Hofman P, Bahadoran P, Bertolotto C, Ballotti R (2011) Mitf is the key molecular switch between mouse or human melanoma initiating cells and differentiated progeny. Oncogene 30(20):2307-2318. doi: 10.1038/onc.2010.598
26. Javelaud D, Alexaki VI, Pierrat MJ, Hoek KS, Dennler S, Van Kempen L, Bertolotto C, Ballotti R, Saule S, Delmas V, Mauviel A (2011) GLI2 and M-MITF transcription factors control exclusive gene expression programs and inversely regulate invasion in human melanoma cells. Pigment Cell Melanoma Res 24(5):932-943. doi: 10.1111/j.1755-148X.2011.00893.x
27. Lister JA, Capper A, Zeng Z, Mathers ME, Richardson J, Paranthaman K, Jackson IJ, Patton EE (2014) A conditional zebrafish MITF mutation reveals MITF levels are critical for melanoma promotion vs. regression in vivo. J Invest Dermatol 134:133-140. doi: 10.1038/jid.2013.293
28. Hoek KS, Goding CR (2010) Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res 23(6):746-759. doi: 10.1111/j.1755-148X.2010.00757.x
29. Hemesath TJ, Steingrimsson E, McGill G, Hansen MJ, Vaught J, Hodgkinson CA, Arnheiter H, Copeland NG, Jenkins NA, Fisher DE (1994) Microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. Genes Dev 8(22):2770-2780
30. Amae S, Fuse N, Yasumoto K, Sato S, Yajima I, Yamamoto H, Udono T, Durlu YK, Tamai M, Takahashi K, Shibahara S (1998) Identification of a novel isoform of microphthalmia-associated transcription factor that is enriched in retinal pigment epithelium. Biochem Biophys Res Commun 247(3):710-715
31. Udono T, Yasumoto K, Takeda K, Amae S, Watanabe K, Saito H, Fuse N, Tachibana M, Takahashi K, Tamai M, Shibahara S (2000) Structural organization of the human microphthalmia-associated transcription factor gene containing four alternative promoters. Biochim Biophys Acta 1491(1-3):205-219
32. Fuse N, Yasumoto KI, Takeda K, Amae S, Yoshizawa M, Udono T, Takahashi K, Tamai M, Tomita Y, Tachibana M, Shibahara S (1999) Molecular cloning of cDNA encoding a novel microphthalmia-associated transcription factor isoform with a distinct amino-terminus. J Biochem 126(6):1043-1051
33. Takeda K, Yasumoto K, Kawaguchi N, Udono T, Watanabe K, Saito H, Takahashi K, Noda M, Shibahara S (2002) Mitf-D, a newly identified isoform, expressed in the retinal pigment epithelium and monocyte-lineage cells affected by Mitf mutations. Biochim Biophys Acta 1574(1-3):15-23
34. Oboki K, Morii E, Kataoka TR, Jippo T, Kitamura Y (2002) Isoforms of mi transcription factor preferentially expressed in cultured mast cells of mice. Biochim Biophys Res Commun 290(4):1250-1254
35. Steingrimsson E, Moore KJ, Lamoreux ML, Ferre-D'Amare AR, Burley SK, Zimring DC, Skow LC, Hodgkinson CA, Arnheiter H, Copeland NG, Jenkins NA (1994) Molecular basis of mouse microphthalmia (mi) mutations helps explain their developmental and phenotypic consequences. Nat Genet 8(3):256-263
36. Hershey CL, Fisher DE (2005) Genomic analysis of the Microphthalmia locus and identification of the MITF-J/Mitf-J isoform. Gene 347(1):73-82
37. Takemoto CM, Yoon YJ, Fisher DE (2002) The identification and functional characterization of a novel mast cell isoform of the microphthalmia-associated transcription factor. J Biol Chem 277(33):30244-30252
38. Hodgkinson CA, Moore KJ, Nakayama A, Steingrímsson E, Copeland NG, Jenkins NA, Arnheiter H (1993) Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell 74(2):395-404
39. Tassabehji M, Newton VE, Read AP (1994) Waardenburg syndrome type 2 caused by mutations in the human microphthalmia (MITF) gene. Nat Genet 8(3):251-255
40. Widlund HR, Fisher DE (2003) Microphthalmia-associated transcription factor: a critical regulator of pigment cell development and survival. Oncogene 22(20):3035-3041
41. Wang Y, Radfar S, Liu S, Riker AI, Khong HT (2010) Mitf-Mdel, a novel melanocyte/melanoma-specific isoform of microphthalmia-associated transcription factor-M as a candidate biomarker for melanoma. BMC Med 8:14. doi: 10.1186/1741-7015-8-14
42. Vachtenheim J, Drdova B (2004) A dominant negative mutant of microphthalmia transcription factor (MITF) lacking two transactivation domains suppresses transcription mediated by wild type MITF and a hyperactive MITF derivative. Pigment Cell Res 17(1):43-50
43. Pogenberg V, Ogmundsdottir MH, Bergsteinsdottir K, Schepsky A, Phung B, Deineko V, Milewski M, Steingrimsson E, Wilmanns M (2012) Restricted leucine zipper dimerization and specificity of DNA recognition of the melanocyte master regulator MITF. Genes Dev 26(23):2647-2658. doi: 10.1101/gad.198192.112
44. Goding CR (2000) Mitf from neural crest to melanoma: signal transduction and transcription in the melanocytic lineage. Genes Dev 14(14):1712-1728
45. Harbst K, Lauss M, Cirenajwis H, Winter C, Howlin J, Torngren T, Kvist A, Nodin B, Olsson E, Hakkinen J, Jirstrom K, Staaf J, Lundgren L, Olsson H, Ingvar C, Gruvberger-Saal SK, Saal LH, Jonsson G (2014) Molecular and genetic diversity in the metastatic process of melanoma. J Pathol 233(1):39-50. doi: 10.1002/path.4318
46. Cronin JC, Wunderlich J, Loftus SK, Prickett TD, Wei X, Ridd K, Vemula S, Burrell AS, Agrawal NS, Lin JC, Banister CE, Buckhaults P, Rosenberg SA, Bastian BC, Pavan WJ, Samuels Y (2009) Frequent mutations in the MITF pathway in melanoma. Pigment Cell Melanoma Res 229(4):435-444. doi: 10.1111/j.1755-148X.2009.00578.x
47. Grill C, Bergsteinsdottir K, Ogmundsdottir MH, Pogenberg V, Schepsky A, Wilmanns M, Pingault V, Steingrimsson E (2013) MITF mutations associated with pigment deficiency syndromes and melanoma have different effects on protein function. Hum Mol Genet 22(21):4357-4367. doi: 10.1093/hmg/ddt285
48. Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, Dessen P, d'Hayer B, Mohamdi H, Remenieras A, Maubec E, de la Fouchardiere A, Molinie V, Vabres P, Dalle S, Poulalhon N, Martin-Denavit T, Thomas L, Andry-Benzaquen P, Dupin N, Boitier F, Rossi A, Perrot JL, Labeille B, Robert C, Escudier B, Caron O, Brugieres L, Saule S, Gardie B, Gad S, Richard S, Couturier J, Teh BT, Ghiorzo P, Pastorino L, Puig S, Badenas C, Olsoon H, Ingvar C, Rouleau E, Lidereau R, Bahadoran P, Vielh P, Corda E, Blanche H, Zelenika D, Galan P, Aubin F, Bachollet B, Becuwe C, Berthet P, Bignon YJ, Bonadona V, Bonafe JL, Bonnett-Dupeyron MN, Cambazard F, Chevrant-Breton J, Coupier I, Dalac S, Demange L, d'Incan M, Dugast C, Faivre L, Vincent-Fetita L, Gauthier-Villars M, Gilbert B, Grange F, Grob JJ, Humbert P, Janin N, Joly P, Kerob D, Lasset C, Leroux D, Levang J, Limacher JM, Livideanu C, Longy M, Lortholary A, Stoppa-Lyonnet D, Mansard S, Mansuy L, Marrou K, Mateus C, Maugard C, Meyer N, Nogues C, Souteyrand P, Venat-Bouvet L, Zattara H, Chaudru V, Lenoir GM, Lathrop M, Davidson I, Avril MF, Demenais F, Ballotti R, Bressac-de-Paillerets B, French Familial Melanoma Study Group (2011) A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 480(7375):94-98. doi: 10.1038/nature10539
49. Yokoyama S, Woods SL, Boyle GM, Aoude LG, MacGregor S, Zismann V, Gartside M, Cust AE, Haq R, Harland M, Taylor JC, Duffy DL, Holohan K, Dutton-Regester K, Palmer JM, Bonazzi V, Stark MS, Symmons J, Law MH, Schmidt C, Lanagan C, O'Connor L, Holland EA, Schmidt H, Maskiell JA, Jetann J, Ferguson M, Jenkins MA, Kefford RF, Giles GG, Armstrong BK, Aitken JF, Hopper JL, Whiteman DC, Pharoah PD, Easton DF, Dunning AM, Newton-Bishop JA, Montgomery GW, Martin NG, Mann GJ, Bishop DT, Tsao H, Trent JM, Fisher DE, Hayward NK, Brown KM (2011) A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 480(7375):99-103. doi: 10.1038/nature10630
50. Ghiorzo P, Pastorino L, Queirolo P, Bruno W, Tibiletti MG, Nasti S, Andreotti V, Paillerets BB, Bianchi Scarra G, Genoa Pancreatic Cancer Study Group (2013) Prevalence of the MITF E318 K germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history. Pigment Cell Melanoma Res 26(2):259-262. doi: 10.1111/pcmr.12047
51. Sturm RA, Fox C, McClenahan P, Jagirdar K, Ibarrola-Villava M, Banan P, Abbott NC, Ribas G, Gabrielli B, Duffy DL, Soyer HP (2014) Phenotypic characterization of nevus and tumor patterns in MITF E318 K mutation carrier melanoma patients. J Invest Dermatol 134(1):141-149. doi: 10.1038/jid.2013.272
52. Bismuth K, Maric D, Arnheiter H (2005) MITF and cell proliferation: the role of alternative splice forms. Pigment Cell Res 18(5):349-359
53. Primot A, Mogha A, Corre S, Roberts K, Debbache J, Adamski H, Dreno B, Khammari A, Lesimple T, Mereau A, Goding CR, Galibert MD (2010) ERK-regulated differential expression of the Mitf 6a/b splicing isoforms in melanoma. Pigment Cell Melanoma Res 23(1):93-102. doi: 10.1111/j.1755-148X.2009.00652.x
54. Verastegui C, Bille K, Ortonne JP, Ballotti R (2000) Regulation of the microphthalmia-associated transcription factor by the Waardenburg syndrome type 4 gene, SOX10. J Biol Chem 275(40):30757-30760
55. Zhu S, Wurdak H, Wang Y, Galkin A, Tao H, Li J, Lyssiotis CA, Yan F, Tu BP, Miraglia L, Walker J, Sun F, Orth A, Schulz PG, Wu X (2009) A genomic screen identifies TYRO3 as a MITF regulator in melanoma. Proc Natl Acad Sci USA 106(40):17025-17030. doi: 10.1073/pnas.0909292106
56. Huber WE, Price ER, Widlund HR, Du J, Davies IJ, Wegner M, Fisher DE (2003) A tissue-restricted cAMP transcriptional response: sOX10 modulates alpha-melanocyte-stimulating hormone-triggered expression of microphthalmia-associated transcription factor in melanocytes. J Biol Chem 278(46):45224-45230
57. Saha B, Singh SK, Sarkar C, Bera R, Ratha J, Tobin DJ, Bhadra R (2006) Activation of the Mitf promoter by lipid-stimulated activation of p38-stress signaling to CREB. Pigment Cell Res 19(6):595-605
58. Sakamoto KM, Frank DA (2009) CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy. Clin Cancer Res 15(8):2583-2587. doi: 10.1158/1078-0432.CCR-08-1137
59. Sestakova B, Ondrusova L, Vachtenheim J (2010) Cell cycle inhibitor p21/WAF1/CIP1 as a cofactor of MITF expression in melanoma cells. Pigment Cell Melanoma Res 23(2):238-251. doi: 10.1111/j.1755-148X.2010.00670.x
60. Saito H, Yasumoto KI, Takeda K, Takahashi K, Fukuzaki A, Orikasa S, Shibahara S (2002) Melanocyte-specific microphthalmia-associated transcription factor isoform activates its own gene promoter through physical interaction with lymphoid-enhancing factor 1. J Biol Chem 277(32):28787-28794
61. Bellei B, Pitisci A, Catricala C, Larue L, Picardo M (2010) Wnt/beta-catenin signaling is stimulated by alpha-melanocyte-stimulating hormone in melanoma and melanocyte cells: implication in cell differentiation. Pigment Cell Melanoma Res 24(2):309-325. doi: 10.1111/j.1755-148X.2010.00800.x
62. Tatari MN, De Craene B, Soen B, Taminau J, Vermassen P, Goossens S, Haigh K, Cazzola S, Lambert J, Huylebroeck D, Haigh JJ, Berx G (2014) ZEB2-transgene expression in the epidermis compromises the integrity of the epidermal barrier through the repression of different tight junction proteins. Cell Mol Life Sci 71(18):3599-3609. doi: 10.1007/s00018-014-1589-0
63. Gheldof A, Hulpiau P, van Roy F, De Craene B, Berx G (2012) Evolutionary functional analysis and molecular regulation of the ZEB transcription factors. Cell Mol Life Sci 69(15):2527-2541. doi: 10.1007/s00018-012-0935-3
64. Sanchez-Tillo E, Liu Y, de Barrios O, Siles L, Fanlo L, Cuatrecasas M, Darling DS, Dean DC, Castells A, Postigo A (2012) EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell Mol Life Sci 69(20):3429-3456. doi: 10.1007/s00018-012-1122-2
65. Denecker G, Vandamme N, Akay O, Koludrovic D, Taminau J, Lemeire K, Gheldof A, De Craene B, Van Gele M, Brochez L, Udupi GM, Rafferty M, Balint B, Gallagher WM, Ghanem G, Huylebroeck D, Haigh J, van den Oord J, Larue L, Davidson I, Marine JC, Berx G (2014) Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression. Cell Death Differ 21(8):1250-1261. doi: 10.1038/cdd.2014.44
66. Liu Y, Ye F, Li Q, Tamiya S, Darling DS, Kaplan HJ, Dean DC (2009) Zeb1 represses Mitf and regulates pigment synthesis, cell proliferation, and epithelial morphology. Invest Ophthalmol Vis Sci 50(11):5080-5088. doi: 10.1167/iovs.08-2911
67. Vachtenheim J, Ondrusova L, Borovansky J (2010) SWI/SNF chromatin remodeling complex is critical for the expression of microphthalmia-associated transcription factor in melanoma cells. Biochem Biophys Res Commun 392(3):454-459. doi: 10.1016/j.bbrc.2010.01.048
68. Pierrat MJ, Marsaud V, Mauviel A, Javelaud D (2012) Expression of microphthalmia-associated transcription factor (MITF), which is critical for melanoma progression, is inhibited by both transcription factor GLI2 and transforming growth factor β. J Biol Chem 287(22):17996-18004. doi: 10.1074/jbc.M112.358341
69. Yang G, Li Y, Nishimura EK, Xin H, Zhou A, Guo Y, Dong L, Denning MF, Nickoloff BJ, Cui R (2008) Inhibition of PAX3 by TGF-beta modulates melanocyte viability. Mol Cell 32(4):554-563. doi: 10.1016/j.molcel.2008.11.002
70. He S, Li CG, Slobbe L, Glover A, Marshall E, Baguley BC, Eccles MR (2011) PAX3 knockdown in metastatic melanoma cell lines does not reduce MITF expression. Melanoma Res 21(1):24-34. doi: 10.1097/CMR.0b013e328341c7e0
71. Bonvin E, Falletta P, Shaw H, Delmas V, Goding CR (2012) A phosphatidylinositol 3-kinase-PAX3 axis regulates Brn-2 expression in melanoma. Mol Cell Biol 32(22):4674-4683. doi: 10.1128/MCB.01067-12
72. Liu F, Cao J, Wu J, Sullivan K, Shen J, Ryu B, Xu Z, Wei W, Cui R (2013) Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas. J Invest Dermatol 133(8):2041-2049. doi: 10.1038/jid.2013.32
73. Goodall J, Carreira S, Denat L, Kobi D, Davidson I, Nuciforo P, Sturm RA, Larue L, Goding CR (2008) Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells. Cancer Res 68(19):7788-7794. doi: 10.1158/0008-5472.CAN-08-1053
74. Boyle GM, Woods SL, Bonazzi VF, Stark MS, Hacker E, Aoude LG, Dutton-Regester K, Cook AL, Sturm RA, Hayward NK (2011) Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor. Pigment Cell Melanoma Res 24(3):525-537. doi: 10.1111/j.1755-148X.2011.00849.x
75. Feige E, Yokoyama S, Levy C, Khaled M, Igras V, Lin RJ, Lee S, Widlund HR, Granter SR, Kung AL, Fisher DE (2011) Hypoxia-mediated transcriptional repression of the melanoma-associated oncogene MITF. Proc Natl Acad Sci USA 108(43):E924-E933. doi: 10.1073/pnas.1106351108
76. Busca R, Berra E, Gaggioli C, Khaled M, Bille K, Marchetti B, Thyss R, Fitsialos G, Larribere L, Bertolotto C, Virolle T, Barbry P, Pouyssegur J, Ponzio G, Ballotti R (2005) Hypoxia-inducible factor 1α is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. J Cell Biol 170(1):49-59
77. Mills CN, Joshi SS, Niles RM (2009) Expression and function of hypoxia inducible factor-1 alpha in human melanoma under non-hypoxic conditions. Mol Cancer 8:104. doi: 10.1186/1476-4598-8-104
78. Hwang I, Park JH, Park HS, Choi KA, Seol KC, Oh SI, Kang S, Hong S (2013) Neural stem cells inhibit melanin production by activation of Wnt inhibitors. J Dermatol Sci 72(3):274-283. doi: 10.1016/j.jdermsci.2013.08.006
79. Hartman ML, Talar B, Noman Z, Gajos-Michniewicz A, Chouaib S, Czyz M (2014) Gene expression profiling identifies microphthalmia-associated transcription factor (MITF) and Dickkopf-1 (DKK1) as regulators of microenvironment-driven alterations in melanoma phenotype. PLoS One 9(4):e95157. doi: 10.1371/journal.pone.0095157
80. Shah M, Bhoumik A, Goel V, Dewing A, Breitwieser W, Kluger H, Krajewski S, Krajewska M, Dehart J, Lau E, Kallenberg DM, Jeong H, Eroshkin A, Bennett DC, Chin L, Bosenberg M, Jones N, Ronai ZA (2010) A role for ATF2 in regulating MITF and melanoma development. PLoS Genet 6(12):e1001258. doi: 10.1371/journal.pgen.1001258
81. Anghel SI, Correa-Rochal R, Budinska E, Boligan KF, Abraham S, Colombetti S, Fontao L, Mariotti A, Rimoldi D, Ghanem GE, Fisher DE, Levy F, Delorenzi M, Piguet V (2012) Breast cancer suppressor candidate-1 (BCSC-1) is a melanoma tumor suppressor that down regulates MITF. Pigment Cell Melanoma Res 25(4):482-487. doi: 10.1111/j.1755-148X.2012.01018.x
82. Son J, Kim M, Jou I, Park KC, Kang HY (2014) IFN-γ inhibits basal and α-MSH-induced melanogenesis. Pigment Cell Melanoma Res 27(2):201-208. doi: 10.1111/pcmr.12190
83. Craig EA, Spiegelman VS (2011) Inhibition of coding region determinant binding protein sensitizes melanoma cells to chemotherapeutic agents. Pigment Cell Melanoma Res 25(1):83-87. doi: 10.1111/j.1755-148X.2011.00921.x
84. Bemis LT, Chen R, Amato CM, Classen EH, Robinson SE, Coffey DG, Erickson PF, Shellman YG, Robinson WA (2008) MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Res 68(5):1362-1368. doi: 10.1158/0008-5472.CAN-07-2912
85. Luo C, Tetteh PW, Merz PR, Dickes E, Abukiwan A, Hotz-Wagenblatt A, Holland-Cunz S, Sinnberg T, Schittek B, Schadendorf D, Diederichs S, Eichmuller SB (2013) miR-137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genes. J Invest Dermatol 133(3):768-775. doi: 10.1038/jid.2012.357
86. Segura MF, Hanniford D, Menendez S, Reavie L, Zou X, Alvarez-Diaz S, Zakrzewski J, Blochin E, Rose A, Bogunovic D, Polsky D, Wei J, Lee P, Belitskaya-Levy I, Bhardwaj N, Osman I, Hernando E (2009) Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci USA 106(6):1814-1819. doi: 10.1073/pnas.0808263106
87. Yan D, Dong XD, Chen X, Yao S, Wang L, Wang J, Wang C, Hu DN, Qu J, Tu L (2012) Role of microRNA-182 in posterior uveal melanoma: regulation of tumor development through MITF, BCL2 and cyclin D2. PLoS One 7(7):e40967. doi: 10.1371/journal.pone.0040967
88. Haflidadottir BS, Bergsteinsdottir K, Praetorius C, Steingrimsson E (2010) miR-148 regulates Mitf in melanoma cells. PLoS One 5(7):e11574. doi: 10.1371/journal.pone.0011574
89. Luo C, Merz PR, Chen Y, Dickes E, Pscherer A, Schadendorf D, Eichmuller SB (2013) MiR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2. Cancer Lett 341(2):240-247. doi: 10.1016/j.canlet.2013.08.021
90. Guo J, Zhang JF, Wang WM, Cheung FW, Lu YF, Ng CF, Kung HF, Liu WK (2014) MicroRNA-218 inhibits melanogenesis by directly suppressing microphthalmia-associated transcription factor expression. RNA Biol 11(6):732-741
91. Gajos-Michniewicz A, Duechler M, Czyz M (2014) MiRNA in melanoma-derived exosomes. Cancer Lett 347(1):29-37. doi: 10.1016/j.canlet.2014.02.004
92. Wu M, Hemesath TJ, Takemoto CM, Horstmann WA, Wells AG, Price ER, Fisher DZ, Fisher DE (2000) c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev 14(3):301-312
93. Takeda K, Takemoto C, Kobayashi I, Watanabe A, Nobukuni Y, Fisher DE, Tachibana M (2000) Ser298 of MITF, a mutation site in Waardenburg syndrome type 2, is a phosphorylation site with functional significance. Hum Mol Genet 9(1):125-132
94. Terragni J, Nayak G, Banerjee S, Medrano JL, Graham JR, Brennan JF, Sepulveda S, Cooper GM (2011) The E-box binding factors Max/Mnt, MITF, and USF1 act coordinately with FoxO to regulate expression of proapoptotic and cell cycle control genes by phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3 signaling. J Biol Chem 286(42):36215-36227. doi: 10.1074/jbc.M111.246116
95. Mansky KC, Sankar U, Han J, Ostrowski MC (2002) Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-kappa B ligand signaling. J Biol Chem 277(13):11077-11083
96. Levy C, Khaled M, Fisher DE (2006) MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med 12(9):406-414
97. Levy C, Sonnenblick A, Razin E (2003) Role played by microphthalmia transcription factor phosphorylation and its zip domain in its transcriptional inhibition by PIAS3. Mol Cell Biol 23(24):9073-9080
98. Levy C, Lee YN, Nechushtan H, Schueler-Furman O, Sonnenblick A, Hacohen S, Razin E (2006) Identifying a common molecular mechanism for inhibition of MITF and STAT3 by PIAS3. Blood 107(7):2839-2845
99. Xu W, Gong L, Haddad MM, Bischof O, Campisi J, Yeh ET, Medrano EE (2000) Regulation of microphthalmia-associated transcription factor MITF protein levels by association with the ubiquitin-conjugating enzyme hUBC9. Exp Cell Res 255(2):135-143
100. Liu F, Singh A, Yang Z, Garcia A, Kong Y, Meyskens FL Jr (2010) MiTF links Erk1/2 kinase and p21CIP1/WAF1 activation after UVC radiation in normal human melanocytes and melanoma cells. Mol Cancer 9:214. doi: 10.1186/1476-4598-9-214
101. Wellbrock C, Rana S, Paterson H, Pickersgill H, Brummelkamp T, Marais R (2008) Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS One 3(7):e2734. doi: 10.1371/journal.pone.0002734
102. Zhao X, Fiske B, Kawakami A, Li J, Fisher DE (2011) Regulation of MITF stability by the USP13 deubiquitinase. Nat Commun 2:414. doi: 10.1038/ncomms1421
103. Larribere L, Hilmi C, Khaled M, Gaggioli C, Bille K, Auberger P, Ortonne JP, Ballotti R, Bertolotto C (2005) The cleavage of microphthalmia-associated transcription factor, MITF, by caspases plays an essential role in melanocyte and melanoma cell apoptosis. Genes Dev 19(17):1980-1985
104. Murakami H, Arnheiter H (2005) Sumoylation modulates transcriptional activity of MITF in a promoter-specific manner. Pigment Cell Res 18(4):265-277
105. Miller AJ, Levy C, Davis IJ, Razin E, Fisher DE (2005) Sumoylation of MITF and its related family members TFE3 and TFEB. J Biol Chem 280(1):146-155
106. Wang F, Marshall CB, Ikura M (2013) Transcriptional/epigenetic regulator CBP/p300 in tumorigenesis: structural and functional versatility in target recognition. Cell Mol Life Sci 70(21):3989-4008. doi: 10.1007/s00018-012-1254-4
107. Keenen B, Qi H, Saladi SV, Yeung M, de la Serna IL (2010) Heterogeneous SWI/SNF chromatin remodeling complexes promote expression of microphthalmia-associated transcription factor target genes in melanoma. Oncogene 29(1):81-92. doi: 10.1038/onc.2009.304
108. Ondrusova L, Vachtenheim J, Reda J, Zakova P, Benkova K (2013) MITF-independent pro-survival role of BRG1-containing SWI/SNF complex in melanoma cells. PLoS ONE 8(1):e54110. doi: 10.1371/journal.pone.0054110
109. Mascarenhas JB, Littlejohn EL, Wolsky RJ, Young KP, Nelson M, Salgia R, Lang D (2010) PAX3 and SOX10 activate MET receptor expression in melanoma. Pigment Cell Melanoma Res 23(2):225-237. doi: 10.1111/j.1755-148X.2010.00667.x
110. Schepsky A, Bruser K, Gunnarsson GJ, Goodall J, Hallsson JH, Goding CR, Steingrimsson E, Hecht A (2006) The microphthalmia-associated transcription factor Mitf interacts with beta-catenin to determine target gene expression. Mol Cell Biol 26(23):8914-8927
111. Genovese G, Ghosh P, Li H, Rettino A, Sioletic S, Cittadini A, Sgambato A (2012) The tumor suppressor HINT1 regulates MITF and β-catenin transcriptional activity in melanoma cells. Cell Cycle 11(11):2206-2215. doi: 10.4161/cc.20765
112. Wardwell-Ozgo J, Dogruluk T, Gifford A, Zhang Y, Heffernan TP, van Doorn R, Creighton CJ, Chin L, Scott KL (2014) HOXA1 drives melanoma tumor growth and metastasis and elicits an invasion gene expression signature that prognosticates clinical outcome. Oncogene 33(8):1017-1026. doi: 10.1038/onc.2013.30
113. Kholmanskikh O, van Baren N, Brasseur F, Ottaviani S, Vanacker J, Arts N, van der Bruggen P, Coulie P, De Plaen E (2010) Interleukins 1α and 1β secreted by some melanoma cell lines strongly reduce expression of MITF-M and melanocyte differentiation antigens. Int J Cancer 127:1625-1636. doi: 10.1002/ijc.25182
114. Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, Frederick DT, Barzily-Rokni M, Straussman R, Haq R, Fisher DE, Mesirov JP, Hahn WC, Flaherty KT, Wargo JA, Tamayo P, Garraway LA (2014) A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov 4(7):816-827. doi: 10.1158/2159-8290.CD-13-0424
115. Pouryazdanparast P, Brenner A, Haghighat Z, Guitart J, Rademaker A, Gerami P (2012) The role of 8q24 copy number gains and C-MYC expression in amelanotic cutaneous melanoma. Mod Pathol 25(9):1221-1226. doi: 10.1038/modpathol.2012.75
116. Jane-Valbuena J, Widlund HR, Perner S, Johnson LA, Dibner AC, Lin WM, Baker AC, Nazarian RM, Vijayendran KG, Sellers WR, Hahn WC, Duncan LM, Rubin MA, Fisher DE, Garraway LA (2010) An oncogenic role for ETV1 in melanoma. Cancer Res 70(5):2075-2084. doi: 10.1158/0008-5472.CAN-09-3092
117. Nicholas C, Yang J, Peters SB, Bill MA, Baiocchi RA, Yan F, Sif S, Tae S, Gaudio E, Wu X, Grever MR, Young GS, Lesinski GB (2013) PRMT5 is upregulated in malignant and metastatic melanoma and regulates expression of MITF and p27Kip1. PLoS One 8(9):e74710. doi: 10.1371/journal.pone.0074710
118. Lin DC, Xu L, Ding LW, Sharma A, Liu LZ, Yang H, Tan P, Vadgama J, Karlan BY, Lester J, Urban N, Schummer M, Doan N, Said JW, Sun H, Walsh M, Thomas CJ, Patel P, Yin D, Chan D, Koeffler HP (2013) Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers. Proc Natl Acad Sci USA 110(15):6109-6114. doi: 10.1073/pnas.1218206110
119. Perego M, Tortoreto M, Tragni G, Mariani L, Deho P, Carbone A, Santinami M, Patuzzo R, Mina PD, Villa A, Pratesi G, Cossa G, Perego P, Daidone MG, Alison MR, Parmiani G, Rivoltini L, Castelli C (2010) Heterogenous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cells. J Invest Dermatol 130(7):1877-1886. doi: 10.1038/jid.2010.69
120. Ramgolam K, Lauriol J, Lalou C, Lauden L, Michel L, de la Grange P, Khatib AM, Aoudjit F, Charron D, Alcaide-Loridan C, Al-Daccak R (2011) Melanoma spheroids grown under neural crest cell conditions are highly plastic migratory/invasive tumor cells endowed with immunomodulator function. PLoS One 6(4):e18784. doi: 10.1371/journal.pone.0018784
121. Sztiller-Sikorska M, Koprowska K, Jakubowska J, Zalesna I, Stasiak M, Duechler M, Czyz M (2012) Sphere formation and capacity of melanoma cells is affected by the microenvironment. Melanoma Res 22(3):215-224. doi: 10.1097/CMR.0b013e3283531317
122. Ghislin S, Deshayes F, Lauriol J, Middendorp S, Martins I, Al-Daccak R, Alcaide-Loridan C (2012) Plasticity of melanoma cells induced by neural cell crest conditions and three-dimensional growth. Melanoma Res 22(3):184-194. doi: 10.1097/CMR.0b013e328351e7c4
123. Ennen M, Keime C, Kobi D, Mengus G, Lipsker D, Thibault-Carpentier C, Davidson I (2014) Single-cell expression signatures reveal melanoma cell heterogeneity. Oncogene. doi: 10.1038/onc.2014.262
124. Somasundaram R, Villanueva J, Herlyn M (2012) Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations. Adv Pharmacol 65:335-359. doi: 10.1016/B978-0-12-397927-8.00011-7
125. Flaherty KT, Hodi FS, Fisher DE (2012) From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 12(5):349-361. doi: 10.1038/nrc3218
126. Haq R, Fisher DE (2013) Targeting melanoma by small molecules: challenges ahead. Pigment Cell Melanoma Res 26(4):464-469. doi: 10.1111/pcmr.12109
127. Shtivelman E, Davies MQ, Hwu P, Yang J, Lotem M, Oren M, Flaherty KT, Fisher DE (2014) Pathways and therapeutic targets in melanoma. Oncotarget 5(7):1701-1752
128. Sztiller-Sikorska M, Koprowska K, Majchrzak K, Hartman M, Czyz M (2014) Natural compounds' activity against cancer stem-like or fast-cycling melanoma cells. PLoS One 9(3):e90783. doi: 10.1371/journal.pone.0090783
129. Syed DN, Afaq F, Maddodi N, Johnson JJ, Sarfaraz S, Ahmad A, Setaluri V, Mukhtar H (2011) Inhibition of human melanoma cell growth by the dietary flavonoid fisetin is associated with disruption of Wnt/β-catenin signaling and decreased Mitf levels. J Invest Dermatol 131(6):1291-1299. doi: 10.1038/jid.2011.6
130. Botton T, Puissant A, Cheli Y, Tomic T, Giuliano S, Fajas L, Deckert M, Ortonne JP, Bertolotto C, Tartare-Deckert S, Ballotti R, Rocchi S (2011) Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth. Cell Death Differ 18(1):109-121. doi: 10.1038/cdd.2010.75
131. Villareal MO, Han J, Ikuta K, Isoda H (2012) Mechanisms of Mitf inhibition and morphological differentiation effects of hirsein A on B16 melanoma cells revealed by DNA microarray. J Dermatol Sci 67(1):26-36. doi: 10.1016/j.jdermsci.2012.04.005
132. Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Donahue MK, Narayan R, Flaherty KT, Wargo JA, Root DE, Garraway LA (2013) A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 504(7478):138-142. doi: 10.1038/nature12688
133. Chen G, Davies MA (2014) Targeted therapy resistance mechanisms and therapeutic implications in melanoma. Hematol Oncol Clin N Am 28:523-536. doi: 10.1016/j.hoc.2014.03.001
134. Roesch A (2014) Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma. Oncogene. doi: 10.1038/onc.2014.249
135. Smith MP, Ferguson J, Arozarena I, Hayward R, Marais R, Chapman A, Hurlstone A, Wellbrock C (2013) Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma. J Natl Cancer Inst 105(1):33-46. doi: 10.1093/jnci/djs471
136. Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, Place CS, Taylor-Weiner A, Whittaker S, Kryukov GV, Hodis E, Rosenberg M, McKenna A, Cibulskis K, Farlow D, Zimmer L, Hillen U, Gutzmer R, Goldinger SM, Ugurel S, Gogas HJ, Egberts F, Berking C, Trefzer U, Loquai C, Weide B, Hassel JC, Gabriel SB, Carter SL, Getz G, Garraway LA, Schadendorf D, Dermatologic Cooperative Oncology Group of Germany (2014) The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 4(1):94-109. doi: 10.1158/2159-8290.CD-13-0617
137. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk WW, Lizee G, Murphy GF, Hwu P, Flaherty KT, Fisher DE, Wargo JA (2013) BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 19(5):1225-1231. doi: 10.1158/1078-0432.CCR-12-1630
138. Yokoyama S, Feige E, Poling LL, Levy C, Widlund HR, Khaled M, Kung AL, Fisher DE (2008) Pharmacological suppression of MITF expression via HDAC inhibitors in the melanocyte lineage. Pigment Cell Melanoma Res 21(4):457-463. doi: 10.1111/j.1755-148X.2008.00480.x